Semaglutide

This study conducted a retrospective analysis to evaluate the effects of outpatient interventions in patients with metabolic syndrome. The specific interventions and doses are not detailed in the abstract. The outcomes measured and their significance are not reported in the abstract.

This study evaluated the pharmacokinetics of oral semaglutide in healthy subjects under different food conditions. The findings indicate variations in absorption based on food intake. No therapeutic claims are made.

This study assessed genetic variability as a predictor for response to GLP-1 treatment in patients. The specific dose of Semaglutide and the population characteristics were not detailed in the abstract. The findings regarding treatment response were not reported in the abstract.

This pilot study evaluated the safety, tolerability, and effectiveness of the Aqua Medical Circumferential RF Vapor Ablation System for duodenal mucosal ablation in patients with insulin-requiring Type 2 Diabetes Mellitus. The specific outcomes measured were not detailed in the abstract. The study's findings are relevant for understanding potential new interventions in diabetes management.

The REVERT-PREDIABETES trial evaluated the effects of semaglutide on individuals with prediabetes. The study aimed to assess the reversal of prediabetes to normoglycemia. Not reported in abstract.

This study emulates the STEP-HFpEF DM heart failure trial using healthcare claims data. It aims to analyze the outcomes associated with semaglutide in patients with heart failure with preserved ejection fraction and diabetes. No specific numeric results or treatment effects are reported in the abstract.

This study examines the impact of antiobesity medications on appetite and related hormones and metabolites. The specific medication studied is Semaglutide, although details on the population, dose, and outcomes are not provided in the abstract. The findings regarding appetite modulation and hormonal changes are not explicitly stated.

This study investigates the pharmacogenetic factors influencing the response to GLP-1 receptor agonists in Mexican-Americans with prediabetes. The specific outcomes measured were not detailed in the abstract. The study is categorized as a Phase 4 trial.

This study evaluated the effects of dual GIP/GLP-1 receptor agonist therapy on weight loss in patients with endometrial cancer and obesity, overweight, with or without diabetes. The specific dose and duration of treatment were not reported in the abstract. The outcomes measured included weight loss and other metabolic parameters.

This study evaluated the safety and efficacy of Semaglutide and the fixed-dose combination of Cilofexor and Firsocostat in subjects with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH). The study was randomized, double-blind, and placebo-controlled. Specific numeric outcomes were not reported in the abstract.

Not reported in abstract.

Not reported in abstract.

Semaglutide may lead to a significant weight reduction of 12.4% over 24 months in a real-world setting, but individual results can vary.

Not reported in abstract.